Clinical and Investigative Medicine最新文献

{"title":"Positive Predictive Value of Primary Subarachnoid Hemorrhage Diagnoses on Death Certificates.","authors":"Shane English,&nbsp;Carl van Walraven Van Walraven","doi":"10.25011/cim.v45i3.38874","DOIUrl":"https://doi.org/10.25011/cim.v45i3.38874","url":null,"abstract":"<p><strong>Purpose: </strong>Epidemiological studies of primary subarachnoid hemorrhage (pSAH) frequently include population-based death registries for case finding. The positive predictive value of pSAH diagnoses in death registries is unknown.</p><p><strong>Methods: </strong>This cross-sectional study identified all people in Ontario, Canada with pSAH listed as a cause of death between 2013 and 2017. pSAH was classified as \"very likely\" if diagnosis of pSAH was confirmed by autopsy, there was a previous hospitalization where pSAH probability exceeded 85% or death was preceded within a week by an emergency room visit where pSAH probability exceeded 25%. pSAH was classified as \"very unlikely\" if previous cerebrovascular imaging had never been done. Remaining cases were classified as \"pSAH status unknown\".</p><p><strong>Results: </strong>1,613 deaths attributed to pSAH were identified (mean 322/year). pSAH classification frequencies were as follows: very likely 528 (32.7%); very unlikely 433 (26.8%); and status unknown 652 (40.4%).</p><p><strong>Conclusion: </strong>We found that a quarter of pSAH cases in our province's death registry were very unlikely to be true pSAH while 40% had unknown veracity. These data should be considered when using death registries for pSAH case finding.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2022-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33489722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overview of The Canadian Clinician Investigator Trainees' Research Presented at CSCI-CITAC Joint Meeting.","authors":"Valera Castanov,&nbsp;Melissa Phuong,&nbsp;Claudia Turco,&nbsp;Sani Eskinazi,&nbsp;Robert Lao,&nbsp;Emmanuelle LeBlanc,&nbsp;Adam Pietrobon,&nbsp;Zacharie Saint-Georges,&nbsp;Wenxuan Wang,&nbsp;Amelia Yuan,&nbsp;Heather Whittaker","doi":"10.25011/cim.v45i3.39271","DOIUrl":"https://doi.org/10.25011/cim.v45i3.39271","url":null,"abstract":"<p><p>The 2021 Annual Joint Meeting (AJM) and Young Investigators' Forum of the Canadian Society for Clinical Investigation / Société Canadienne de Recherches Clinique (CSCI/SCRC) and Clinician Investigator Trainee Association of Canada/Association des Cliniciens-Chercheurs en Formation du Canada (CITAC/ACCFC) was hosted virtually on November 14-16th, 2021. The theme of the AJM was \"Communication, Collaboration, and Tools for the Next Generation of Clinician Scientists\", and emphasized lectures, panels and interactive workshops designed to provide knowledge and skills for professional development of clinician investigator trainees. The opening remarks were given by Nicola Jones (President of CSCI/SCRC) and Adam Pietrobon (Past President of CITAC/ACCFC). The keynote speaker was Dr. Timothy Caulfield, who delivered the presentation titled \"Communication in the Era of Misinformation\". Dr. Michael Hill (University of Calgary) received the CSCI Distinguished Scientist Award and Dr. Philippe Campeau (Université de Montréal) received the CSCI Joe Doupe Young Investigator Award. Each of the scientists delivered award winning talks during the symposium titled \"All the King's Horses and All the King's Men\" and \"Understanding Growth Plate Disorders to Better Treat Them\", respectively. The three interactive workshops included \"Data Visualization\", \"Science Communication on Social Media\" and \"Mentorship in Action\". The two panels were \"CIHR Engagement: Challenges and Opportunities in the Clinician Investigator Career Path\" and \"Early Career Investigator Panel\". The AJM also included presentations from clinician investigator trainees from across the country. Over 60 abstracts were showcased at this year's meeting, most of which are summarized in this review. Six outstanding abstracts were selected for oral presentations during the President's Forum.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2022-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33478115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fall 2022: Clinician Investigator Trainee Association of Canada (CITAC).","authors":"Melissa S Phuong Phuong,&nbsp;Valera Castanov,&nbsp;Claudia Turco,&nbsp;Robert Lao,&nbsp;Wenxuan Wang,&nbsp;Amelia Yuan,&nbsp;Heather Whittaker","doi":"10.25011/cim.v45i3.39272","DOIUrl":"https://doi.org/10.25011/cim.v45i3.39272","url":null,"abstract":"<p><p>On behalf of the Clinical Investigator Trainee Association of Canada (CITAC) Board of Directors, I would like to extend an enthusiastic welcome to our new MD+ trainee members! I hope you soaked up all that summer had to offer and are in good back-to-school spirits. A new academic year is upon us, and opportunities abound for the Canadian physician scientist trainee community.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2022-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33478114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Facilitators and Barriers to Clinical Pathway Uptake and Utilization Among Primary Care Providers in Saskatchewan - A Qualitative Study.","authors":"Gary Groot,&nbsp;Shaliny Ollegasagrem,&nbsp;Mahasti Khakpour,&nbsp;Adel Panahi,&nbsp;Donna Goodridge,&nbsp;Joshua Lloyd,&nbsp;Leigh Kinsman,&nbsp;Thomas Rotter,&nbsp;Zane Tymchak,&nbsp;Tracey Carr","doi":"10.25011/cim.v45i2.38450","DOIUrl":"https://doi.org/10.25011/cim.v45i2.38450","url":null,"abstract":"<p><strong>Purpose: </strong>Clinical Pathways (CPWs) are multidisciplinary, evidence-based, complex interventions designed to standardize patient care. In Saskatchewan, development, implementation and evaluation of the seven provincial CPWs (Hip & Knee, Spine, Pelvic Floor, Prostate Assessment, Fertility Care, Lower Extremity Wound Care and Acute Stroke) present significant challenges, leading to low utilization. This study aimed to identify facilitators and barriers to CPW utilization by Saskatchewan family physicians.</p><p><strong>Methods: </strong>To identify the facilitators and barriers to CPWs, a qualitative interpretive approach consisted of eight one-on-one key informant interviews and five focus groups held with 30 family physicians in two larger urban and two smaller Saskatchewan cities. Inductive, thematic analysis of the interviews based on the Theoretical Domain Framework for behavioral changes was used to identify facilitators and barriers to CPW uptake and utilization.</p><p><strong>Results: </strong>Fifty-one themes were mapped under 14 Theoretical Domain Framework domains. Major barriers included the following: system-level (knowledge and communication, social/professional identity, family physician engagement and education); objective clarification (goals, belief about consequences of implementing CPW); and technical and resource related (administrative, access to local specialists, enforcement and incentives). The most prominent barrier was lack of systematic CPW promotion and inconsistencies in communication between the following: organization-to-practitioner; organization-to-organization; and practitioner-to-practitioner. Facilitators who mitigated barriers were need for optimized and integrated information technology services (i.e., Electronic Medical Records) and optimism towards CPW usage and patient outcomes.</p><p><strong>Conclusions: </strong>This exploratory study identified specific improvements and recommendations required to promote uptake of CPWs based on perceived facilitators and barriers.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2022-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40395975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolomics and Cytokine Analysis for Identification of Schizophrenia with Auditory Hallucination.","authors":"Xinchun Li,&nbsp;Chao Yang,&nbsp;Xiaoli Liang,&nbsp;Dongfeng Li,&nbsp;Zhiqiang Zhou,&nbsp;Huiqiong Xiao,&nbsp;Xuejun Liu,&nbsp;Jie Li,&nbsp;Dong Yang,&nbsp;Meizhi Li","doi":"10.25011/cim.v45i2.38096","DOIUrl":"https://doi.org/10.25011/cim.v45i2.38096","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the metabolic profile and biomarkers of schizophrenia with auditory hallucinations (AHs).</p><p><strong>Methods: </strong>A total of 18 schizophrenic patients with the symptom of pure AHs (pAHs), 28 without AH (nAHs) and 43 age-matched healthy persons (Con) were enrolled in this study. Participants in pAHs and nAHs groups had relapsed into exacerbations of psychosis after self-discontinuing antipsychotics for at least one month; blood samples were drawn prior to restarting anti-psychotic treatment. Participants with history of recreational substance use were excluded. Positive and Negative Syndrome Scale (PANSS) and Auditory Hallucinations Rating Scale (AHRS) were used to assess the clinical mental state of all samples. Enzyme-linked immunosorbent assay (ELISA) was used to estimate the level of cytokines, and metabolomics analysis to identify potential biomarkers and pathways in the three groups. Graphpad 8.0 software was used to calculate the area under the receiver operating characteristic (ROC) curve. The relationship between metabolites and cytokines were determined using correlation analysis.</p><p><strong>Results: </strong>Questionnaire scores showed significant differences in the positive symptom scale and PANSS total between nAHs and pAHs groups. Four cytokines (BDNF, IL-2, NGF-β and TNF-α) differed significantly among the three groups. Six molecules in the nAHs group (phenylalanine, hippurate, serine, glutamate, valine and cystine) and four in the pAHs group (phenylalanine, serine, glutamate and cystine) were identified as potential biomarkers. In addition, phenylalanine was shown as a potential independent diagnostic biomarker for pAHs. Correlation analysis revealed that cystine and serine were significantly negatively correlated with IL-2 in the pAHs group.</p><p><strong>Conclusions: </strong>This study revealed the metabolic profile of patients with schizophrenia with AHs and provided new information to support the diagnosis. The identification of unique biomarkers would contribute to objective and reliable diagnoses of patients with schizophrenia with AH.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2022-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40398901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editor-In-Chief for Clinical and Investigative Medicine.","authors":"The Canadian Society For Clinical Investigation Csci","doi":"10.25011/cim.v45i2.38850","DOIUrl":"https://doi.org/10.25011/cim.v45i2.38850","url":null,"abstract":"The Canadian Society for Clinical Investigation (CSCI) is seeking an Editor-in-Chief for the Society's journal, \"Clinical and Investigative Medicine\". The Canadian Society for Clinical Investigation (CSCI) is seeking an Editor-in-Chief for the Society's journal, \"Clinical and Investigative Medicine\". If you are knowledgeable in the areas of clinical research that span disciplines from fundamental to clinical to population health, and you are keenly interested in encouraging the careers of young investigators, this may provide an exciting opportunity. Editor-in-Chief is an important role for the Society. Clinical and Investigative Medicine (CIM) is a well-established open-access peer-reviewed journal owned by CSCI. The person selected for this role will be responsible for choosing articles based on their scientific quality and for overseeing all aspects of their review and publication. The journal focuses on clinical and research articles that provide insights into the scientific basis for clinical disease processes. The journal also actively supports the careers of young investigators and encourages publication of their work. Five-year Impact Factor: 1.32 Citations: 1,200/year History: 1978-present Published: Four times annually ISSN: 1488-2353 (electronic) NLM ID: 7804071 Indexing: Index Medicus; Medline; and PubMed; v1n1, (1978) to present. Print issues v1n1- v29n5 (2006); electronic issues v30n1-v45n1 (present) Please contact CIM Manager rob@Gallaher.ca for more information.","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2022-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83338280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Muscarinic Receptor Antagonism and Allergen Induced Airway Responses in Allergic Asthma: A Scoping Review.","authors":"Beth E Davis,&nbsp;Kayla J Cropper,&nbsp;Donald W Cockcroft Cockcroft","doi":"10.25011/cim.v45i2.38229","DOIUrl":"https://doi.org/10.25011/cim.v45i2.38229","url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this scoping review was to identify existing clinical and basic science knowledge surrounding the effect of muscarinic receptor antagonism on allergen-induced airway responses to inform future clinical research in this area.</p><p><strong>Methods: </strong>Multiple advanced searches were performed using the National Library of Medicine PubMed search engine. Each search began with two terms; for example, \"atropine and asthma\" or \"tiotropium and airway inflammation\". Results were then further refined to include terms such as \"allergen\" or \"ovalbumin (OVA)\". Abstracts of refined searches were reviewed for relevance to allergic asthma and allergen-induced airway responses including the early and late asthmatic responses, airway inflammation and tissue remodelling. There was no restriction regarding publication date. Reference lists of selected papers were also reviewed for relevant publications.</p><p><strong>Results: </strong>Nine human clinical trial publications and fourteen animal model publications were identified. In humans, single dose atropine (n=4), ipratropium (n=4) or oxitropium (n=1) administered pre-challenge produced equivocal effects on allergen-induced early asthmatic responses as reported but favored inhibition in eight of nine studies after re-analyses. Animal model investigations (n=14) showed mostly favorable results, especially with respect to airway inflammation and tissue remodelling, although two studies were negative, and one study showed a worsening in allergen induced airway inflammation following muscarinic receptor antagonism.</p><p><strong>Conclusion: </strong>Existing human and animal model data suggest muscarinic receptor antagonism may be beneficial in preventing allergen induced airway responses in those with allergic asthma. Additional human research utilizing current standardized methodologies is required.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2022-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40395977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening for Immune-Related RNA Biomarkers of Aneurysmal Subarachnoid Hemorrhage.","authors":"Lin Cheng,&nbsp;Yun Zhao,&nbsp;Hong Ke","doi":"10.25011/cim.v45i2.38449","DOIUrl":"https://doi.org/10.25011/cim.v45i2.38449","url":null,"abstract":"<p><strong>Purpose: </strong>Through comprehensive bioinformatics analysis based on the immune microenvironment, this study aimed to identify immune-related RNA biomarkers that indicate aneurysmal subarachnoid hemorrhage (aSAH).</p><p><strong>Methods: </strong>The GSE73378 dataset was downloaded from the National Center for Biotechnology Information GEO database, providing blood from 107 normal controls and 103 patients with aSAH. The immune infiltration types in the aSAH blood samples were assessed and RNAs that were differentially expressed (DE) between 1) the aSAH and control groups and 2) the immune infiltration groups (high and low) were identified. The intersecting genes were subjected to weighted gene co-expression network analysis followed by co-expression network construction. The aSAH-related genes and pathways were identified from the Comparative Toxicogenomics Database: update 2019.</p><p><strong>Results: </strong>A total of three DE long non-coding RNAs (lncRNAs) and 301 DE mRNAs were identified. Of the 301 mRNAs, 91 were significantly enriched in three modules. Based on the 91 mRNAs and three lncRNAs, a co-expression network related to the disease pathway was constructed. This pathway consisted of 16 factors, including the 13 mRNAs (e.g., TNFSF13B, TNFSF10, MYD88, GNA12 and NSMAF) and three lncRNAs (FAM66A, LINC00954 and CELF2-AS2), as well as six pathways, including the NF-κB, toll-like receptor, and sphingolipid signalling pathways.</p><p><strong>Conclusion: </strong>TNFSF13B, MYD88, GNA12, NSMAF, FAM66A, LINC00954 and CELF2-AS2 may serve as biomarkers for aSAH. The NF-κB, toll-like receptor and sphingolipid signalling pathways may play critical roles in the progression of aSAH.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2022-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40395976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimating Disease Prevalence in Administrative Data.","authors":"Jacek A Kopec","doi":"10.25011/cim.v45i2.38100","DOIUrl":"https://doi.org/10.25011/cim.v45i2.38100","url":null,"abstract":"<p><strong>Purpose: </strong>Disease prevalence estimates from population-based administrative databases are often biased due to measurement (misclassification) errors. The purpose of this article is to review the methodology for estimating disease prevalence in administrative data, with a focus on bias correction.</p><p><strong>Source: </strong>Several approaches to bias correction in administrative data were reviewed and application of these methods was demonstrated using an example from the literature: physician claims and hospitalization data were employed to estimate diabetes prevalence in Ontario, Canada.</p><p><strong>Findings: </strong>Misclassification bias in prevalence estimates from administrative data can be reduced by developing and selecting an optimal algorithm for case identification, applying a bias correction formula, or using statistical modelling. An algorithm for which sensitivity equals positive predictive value provides an unbiased estimate of prevalence. Bias reduction methods generally require information about the measurement properties of the algorithm, such as sensitivity, specificity, or predictive value. These properties depend on disease type, prevalence, algorithm definition (including the observation window), and may vary by population and time. Prevalence estimates can be improved by applying multivariable disease prediction models.</p><p><strong>Conclusion: </strong>Frequency of a positive case identification algorithm in administrative data is generally not equivalent to disease prevalence. Although prevalence estimates can be corrected for bias using known measurement properties of the algorithm, these properties may be difficult to estimate accurately; therefore, disease prevalence estimates based on administrative data must be treated with caution.</p>","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2022-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40398900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between ESR1 XBAI and Breast Cancer Susceptibility: A Systematic Review and Meta-Analysis.","authors":"Tongyou Sunemail, R. Lian, Xiujun Liang, Dayong Sun","doi":"10.25011/cim.v45i1.37842","DOIUrl":"https://doi.org/10.25011/cim.v45i1.37842","url":null,"abstract":"PURPOSE\u0000Estrogen receptor 1 (ESR1) XbaI polymorphisms may affect breast cancer susceptibility; however, the results of previously published studies are inconsistent. This meta-analysis aimed to investigate the relationship between ESR1 XbaI polymorphism and breast cancer risk.  Methods: Articles from the PubMed, Embase, Cochrane Library, WoS, Scopus, Wanfang Data, CNKI, CBM and CQVIP databases were systematically searched to determine the association between ESR1 XbaI polymorphism and breast cancer risk. The pooled results were assessed using odds ratios (ORs) and 95% confidence intervals (CIs), followed by subgroup analysis.  Results: Twenty-two studies involving 12,821 cases and 14,739 control subjects were analyzed. The pooled results indicated that ESR1 XbaI polymorphism may decrease risk of breast cancer in AG vs. AA (co-dominant model: OR = 0.88, 95% CI = 0.79-0.97, P = 0.015) and AG + GG vs. AA models (dominant model: OR = 0.89, 95% CI = 0.80-0.98, P = 0.022). Subgroup analysis indicated significant associations between the ESR1 XbaI polymorphism and breast cancer risk were observed in Asian subjects, non-Hardy-Weinberg equilibrium study, post-menopausal status and hospital-based subgroups under the AG vs. AA and AG + GG vs. AA models (all P < 0.05).  Conclusions: Our analysis of pooled data indicated that AG genotype in ESR1 XbaI may be a protective factor for breast cancer patients in some subgroups.","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2022-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83000104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}